NIP 022
Alternative Names: NIP022; ONO-7746; YHI 1501Latest Information Update: 05 Nov 2023
At a glance
- Originator Nissan Chemical Industries
- Developer Nissan Chemical Industries; Yakult Honsha
- Class Small molecules
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombocytopenia
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for phase-I development in Thrombocytopenia(In volunteers) in Japan (PO, Capsule)
- 01 Jun 2017 Yakult Honsha completes a phase I trial in Thrombocytopenia (In volunteers) in Japan (PO) (JapicCTI163296)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Thrombocytopenia(Chemotherapy-induced) in Russia (PO, Capsule)